Can Wegovy Affect Your Eyesight? What the Evidence Actually Shows

Has NAION actually been linked to semaglutide — and how strong is that evidence?

NAION stands for non-arteritic anterior ischaemic optic neuropathy. It happens when blood flow to the front of the optic nerve is temporarily interrupted, causing sudden, usually painless vision loss in one eye. It is uncommon in the general population. In 2024, a study published in JAMA Ophthalmology found that people prescribed semaglutide for obesity had a roughly fourfold higher rate of NAION diagnoses than people in the same clinic prescribed other weight-loss medicines. That sounds alarming, but the absolute numbers were small: around 20 cases per 10,000 person-years in the semaglutide group.

Researchers were careful to stress that the study was observational. It recorded what happened in a patient population; it could not prove that semaglutide caused the condition. People with obesity already carry higher rates of cardiovascular risk factors that independently raise NAION risk, so separating the drug's effect from the underlying condition is genuinely difficult. The MHRA Yellow Card scheme collects ongoing reports of suspected side effects including ocular ones, and monitoring continues. No formal MHRA safety action specific to NAION in non-diabetic semaglutide users had been issued as of July 2026.

The practical upshot: NAION is in the conversation around Wegovy and eyesight because the signal is real enough to warrant investigation, not because regulators have concluded the drug causes it. If you have a history of NAION or optic nerve problems, that is exactly the kind of detail a prescriber needs to know before treatment starts, and our page covering whether Wegovy can affect eyesight explains the full picture of what is currently known. Our clinical team reviews this kind of history as part of every assessment.

What about people who already have diabetic eye disease?

This is a separate and better-established concern. Diabetic retinopathy (damage to the tiny blood vessels at the back of the eye caused by chronically high blood sugar) is listed in the Wegovy prescribing information as a risk to monitor, particularly in people with type 2 diabetes. Rapid improvements in blood glucose can, paradoxically, temporarily worsen retinopathy. The NHS medicines page for semaglutide notes that patients with a history of diabetic eye problems should tell their prescriber before starting.

This does not mean semaglutide is off-limits for everyone with diabetes-related eye changes, but it does mean the prescriber needs that information. Monitoring may be recommended more frequently. For people using Wegovy purely for weight management without diabetes, diabetic retinopathy is not a personal risk factor, though it is worth noting if there is a strong family history of the condition alongside diabetes.

The broader picture on Wegovy's effects on the body (appetite, metabolism, cardiovascular markers) is covered in more detail on our semaglutide overview page.

Are blurry vision or dry eyes during Wegovy treatment something to worry about?

Anecdotally, some people starting semaglutide report mild visual disturbances in the early weeks: things looking slightly blurred, eyes feeling drier than usual, or a general sense that their vision is a little off. These reports are common enough that many clinicians now mention them, but they are not listed as a formally recognised side effect in the Wegovy patient information leaflet in the same way that nausea or constipation are.

One plausible explanation is fluid redistribution. GLP-1 medicines like semaglutide affect how the body handles water and electrolytes, particularly early in treatment. This can temporarily influence tear film stability, which is one reason dry, gritty eyes may appear. Changes in blood pressure (another early treatment effect) can also subtly alter how the eyes feel. These tend to settle as the body adjusts. Persistent or worsening symptoms are a different matter. Our page on Wegovy and dry eyes goes into this more specifically, and our overview of reported eyesight problems during Wegovy treatment covers the wider range of issues patients mention.

For anyone who finds their vision suddenly changing (not subtly worse, but noticeably and quickly) the right move is same-day medical review. That applies whether or not you can link it directly to your medication. If you are unsure who to contact, our team is available seven days a week and can advise on next steps; reach us via the contact page.

What should you do before and during Wegovy treatment to protect your eyes?

There are some straightforward steps. Before starting, tell your prescriber about any existing eye conditions: diabetic retinopathy, glaucoma, a previous episode of NAION, or anything requiring ongoing ophthalmology follow-up. This is not to block treatment, but to make sure monitoring is proportionate. If you wear contact lenses, dry-eye symptoms early in treatment can make lenses uncomfortable, worth knowing in advance.

During treatment, the key rule is the same as it is for other uncommon but serious side effects: know the warning signs and act quickly if they appear. Sudden, painless loss of vision in one eye, a grey patch or shadow in your visual field, or vision that seems to shift overnight are all reasons to seek urgent help, not to wait and see. These are not normal early side-effects of semaglutide; they need same-day assessment.

For routine eyesight concerns (glasses prescriptions, annual checks) continue attending your optometrist as you normally would. Weight loss itself can, over time, affect prescription in some people (blood glucose changes influence lens shape), so an optometry review at the six-month mark is sensible for anyone whose vision is changing. To read more about Wegovy's broader effects on eye health or to explore whether treatment is right for you, our free consultation is open seven days a week, reviewed the same day by a real prescriber.